

Cell-based therapies offer an attractive approach for revascularization and regeneration of tissues. However, and despite the pressing clinical needs for effective revascularization strategies, the successful immobilization of viable vascular cells within 3D matrices has been difficult to achieve. In this paper the in vitro potential of a natural, injectable RGD-alginate hydrogel as an in situ forming matrix to deliver endothelial cells was evaluated. Several techniques were employed to investigate how these microenvironments could influence the behavior of vascular cells, namely their ability to promote the outward migration of viable, proliferative cells, retaining the ability to form a 3D arrangement. Cells within RGD-grafted alginate hydrogel were able to proliferate and maintained 80% of viability for at least 48 h post-immobilization. Additionally, entrapped cells created a 3D organization into cellular networks and, when put in contact with matrigel, cells migrated out of the RGD-matrix. Overall, the obtained results support the idea that the RGD peptides conjugated to alginate provide a 3D environment for endothelial cells adhesion, survival, migration and organization. © 2011 Elsevier Ltd.
| Engineering uncontrolled terms | 3-D environmentsAlginate hydrogelsAlginate matrixCell-based therapyCellular networkCross-linkableIn-situIn-situ formingIn-vitromatrixMicroenvironmentsProliferative cellsRevascularizationRGD peptideVascular cells |
|---|---|
| Engineering controlled terms: | AdhesionAlginateCell adhesionCell immobilizationCell proliferationCellular neural networksHydrogelsPeptidesScaffolds (biology)Three dimensionalTissue |
| Engineering main heading: | Endothelial cells |
| EMTREE drug terms: | alginic acidangiopoietin 2arginylglycylaspartic acidmatrigelmessenger RNAmolecular scaffoldvon Willebrand factor |
| EMTREE medical terms: | articlecell adhesioncell migrationcell proliferationcell structurecell survivalcell transportcell viabilitycross linkingendothelium cellextracellular matrixgene expressionhumanhuman cellhydrogelimmobilized cellimmunofluorescencein situ crosslinkingin vitro studymicroenvironmentphenotypepriority journalumbilical vein endothelial cell |
| MeSH: | AlginatesAngiopoietin-2Cell MovementCell ProliferationCell ShapeCell SurvivalCells, CulturedCross-Linking ReagentsExtracellular MatrixFluoresceinsHuman Umbilical Vein Endothelial CellsHumansHydrogelsInjectionsMatrix MetalloproteinasesOligopeptidesSolutionsSuccinimides |
alginic acid, 28961-37-7, 29894-36-8, 9005-32-7, 9005-38-3; angiopoietin 2, 194368-66-6; arginylglycylaspartic acid, 99896-85-2; matrigel, 119978-18-6; von Willebrand factor, 109319-16-6;
5-(6)-carboxyfluorescein diacetate succinimidyl ester; Alginates; Angiopoietin-2; Cross-Linking Reagents; Fluoresceins; Hydrogels; Matrix Metalloproteinases, 3.4.24.-; Oligopeptides; Solutions; Succinimides; arginyl-glycyl-aspartic acid, 99896-85-2
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| Fuel Cell Technologies Program | POCTI/SAU-BMA/55556/2004,FCOMP-01-0124-FEDER-010915,SFRH/BD/22307/2005,PTDC/SAU-BEB/101235/2008 | FCT |
The authors are grateful to the Portuguese Foundation for Science and Technology (FCT) for awarding S.J. Bidarra a scholarship SFRH/BD/22307/2005. This work was carried out under contract POCTI/SAU-BMA/55556/2004 and PTDC/SAU-BEB/101235/2008 and FCOMP-01-0124-FEDER-010915.
Granja, P.L.; INEB-Instituto de Engenharia Biomédica, Rua do Campo Alegre, n 823, Portugal;
© Copyright 2012 Elsevier B.V., All rights reserved.
© MEDLINE® is the source for the MeSH terms of this document.